A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

Kindler, H.L. ; Richards, D.A. ; Garbo, L.E. ; Garon, E.B. ; Stephenson, J.J. ; Rocha-Lima, C.M. ; Safran, H. ; Chan, D. ; Kocs, D.M. ; Galimi, F. ; McGreivy, J. ; Bray, S.L. ; Hei, Y. ; Feigal, E.G. ; Loh, E. ; Fuchs, C.S.

Annals of oncology, 2012-11, Vol.23 (11), p.2834-2842 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível